Physician profile
Jonathan Nelson Bailey
NPI 1083330914
$2,167.21
in general payments reported to CMS, 2019-2025
24 companies · $860 in 2025
The $860 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $353 · 2024: $955 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,167.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $484.05 | 2023-2025 | |
| Axsome Therapeutics, INC. | $308.00 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $218.91 | 2023-2024 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $163.48 | 2024-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $155.53 | 2024-2025 | |
| Novo Nordisk INC | $124.09 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $118.99 | 2024-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $105.30 | 2024-2025 | |
| Pfizer INC. | $67.62 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $65.31 | 2024-2025 | Voquezna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.68 | 2024 | Rexulti |
| Amgen INC. | $43.97 | 2024-2025 | Prolia, Evenity, Otezla |
| Xeris Pharmaceuticals, INC. | $34.98 | 2024-2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $34.23 | 2024-2025 | Inspire |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.50 | 2023 | Xifaxan |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $27.98 | 2025 | Inceptiv |
| Boston Scientific Corporation | $23.77 | 2023 | Ams 700 Cxr Rte Kit |
| Insulet Corporation | $17.95 | 2025 | Omnipod |
| Philips North America LLC | $16.60 | 2024 | (Ck7) Extended Holter |
| Baxter Healthcare | $16.38 | 2024 | Hillrom - Monarch Airway Clearance System |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.24 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $15.57 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $15.14 | 2024 | Quviviq |
| Daiichi Sankyo INC. | $13.94 | 2025 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.